SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39 3 ) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39 3 ) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Sun Pharma shares: Jefferies sees healthy upside after recent acquisition
Sun Pharma recently completed the acquisition of US-based Concert Pharmaceuticals SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39 (3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 28, 2023 for Aditya Medisales Ltd
Sun Pharma may incur revenue loss for ransomware incident on March 2
Sun Pharma Advanced Research Company may incur expenses in connection with incident; India was the second most attacked country for ransomware in the APAC-Japan region in 2022 SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Closure of Trading Window
This is to inform you that in compliance with the Company's Code of Conduct for Prevention of Insider Trading, the window closure for trading by Designated Persons of the Company (along with his/her immediate relatives or any person with whom he/she shares a material financial relationship), shall be with effect from Saturday, April 1, 2023 till 48 hours after the declaration of Audited Financial Results of the Company for the year ended March 31, 2023. The date of the Board Meeting of the Company for declaration of the Audited Financial Results of the Company for the year ended March 31, 2023 will be intimated in due course. This is for your information and record. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Further To Our Intimation Filed On 2Nd March 2023, Regarding An Information Technology ('IT') Security Incident, We Wish To Provide An Update.
Further to our intimation filed on 2nd March 2023, regarding an Information Technology ('IT') security incident, we wish to provide an update. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015